Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said its subsidiary, Jinzhou Avanc Pharmaceutical, obtained marketing registration approval from China's National Medical Products Administration for its Metaraminol Bitartrate Injection.
The drug is mainly used for prevention and treatment of hypotension, according to a Monday disclosure with the Hong Kong Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.